Skin Cancer News
A more than 2-fold increased risk of prostate cancer was seen for patients whose first melanoma diagnosis was 10 to 15 years before study recruitment.
Adjuvant pembrolizumab improved quality of life when compared with ipilimumab or high-dose interferon α 2b.
Roughly half of hospitals accredited by the ACS-CoC failed to disclose the cost of 5 common cancer surgeries, researchers found.
A systematic review of clinical practice guidelines revealed substantial variation in recommendations for follow-up after initial treatment for keratinocyte carcinoma.
Researchers identified a subset of melanoma patients with stage I lesions and negative clinical nodes who had a very low risk of death.
Relatlimab plus nivolumab yields a high pathologic complete response rate in resectable stage III or oligometastatic stage IV melanoma, a phase 2 study suggests.
Patients with breast implants are at risk of developing squamous cell carcinoma and various types of lymphoma in the capsules around the implants.
For patients with melanoma, socioeconomic disparities persist within insured populations, specifically those in nonintegrated health care systems.
Current evidence is insufficient for assessing the balance of benefits and harms of screening for asymptomatic teens and adults.
COVID-19 vaccination is safe for cancer patients receiving immune checkpoint inhibitors and should not interrupt therapy, according to researchers.
Inpatient treatment with immune checkpoint inhibitors is associated with poor survival outcomes in patients with advanced cancer.
The optimal sequence of treatment for BRAF-mutant melanoma is nivolumab-ipilimumab followed by dabrafenib-trametinib, a study suggests.
Researchers at Brigham and Women’s Hospital investigated the skin cancer prevention behaviors of these rarely studied ethnic groups.
SBRT did not improve the efficacy of nivolumab-ipilimumab in patients with advanced Merkel cell carcinoma in a phase 2 study.
The approvals were based on data from the LIBRETTO-001 trial.
Neoadjuvant plus adjuvant pembrolizumab can prolong event-free survival vs adjuvant pembrolizumab alone in resectable melanoma.
Untreated sleep apnea may be a risk factor for cancer, according to researchers.
Researchers compared biomarker and nonbiomarker clinical trials in oncology and identified differences in timelines and the risk of failure.
Tumor-infiltrating lymphocytes can improve progression-free survival, when compared with ipilimumab, in patients with advanced melanoma, a phase 3 trial suggests.
Following an initial extensive review, the FDA identified less than 20 cases of SCC and less than 30 cases of various lymphomas in the capsule around the breast implant.